Shilpa Medicare: Nod For Blood Clot, Heart Attack Drug | Vishnukant Bhudata | Business News #ETNOW
Shilpa Medicare: Nod For Blood Clot, Heart Attack Drug | Vishnukant Bhudata | Business News
Shilpa Medicare secures EMA approval for world’s first Rivaroxaban orodispersible film, targeting $2.5B EU market with launch in 9-12 months. Key growth: complex APIs (oncology, peptides), formulations (2 US 505(b)(2) launches), biologics (CDMO, biosimilars), and recombinant albumin (Phase 3 completion 2026-27). Nor UDCA for NAFLD launches Q4 2025 via Indian partnerships.
#shilpamedicare #rivaroxabanodf #emaapproval #nafldtreatment #norudca #recombinantalbumin #biologicsgrowth #pharmainnovation #biosimilars #oncologydrugs #etnow
control your money with economic times now.
YouTube Channel – https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC
Website – https://ift.tt/sNFpLGO
Follow us on Google News for latest updates
ET Now: https://ift.tt/rxEAcP4
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
Thank you for your support in keeping this website running.💛
View on “Tokyo Trend News”
コメントを送信